Mar. 16 at 5:35 PM
$SLS $SLS $SLS Just the Secondary Asset here, SLS009 is worth 5X the Entire SLS Market Value.
$GILD bought
$FTSV for
$4.9B based on Phase 1B AML-MR Data for NEWLY DIAGNOSED PATIENTS Published at ASH.
$SLS published Phase 2B AML-MR Data at ASH 2025, for Patients that FAILED AZA+VEN that is Much Better, similar ORR and Longer Survival, without the Toxicity - again In an AzaVEN Failed Setting, vs Newly DXD.
Big Pharma's Know SLS009 is already worth 5X the entire SLS Market Cap -
$BAYRY $ABBV have been trying to Develop a CDKinase Inhibtor for AML for Over a Decade, they've all Been TOXIC -- 009 is the First Ever Safe CDK9 Inhibitor, Ever. 80 Patient p1 7Patient p2 ....
Rinvoq - Kisquali - Verzenio .... all kinase inhibitors worth tens of billions.